CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key FactsZacks Investment Research • 04/22/26
CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy?The Motley Fool • 04/21/26
CRISPR Therapeutics AG (CRSP) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptSeeking Alpha • 04/13/26
This Biotech Has a Pipeline That Could Redefine Its Entire Therapeutic AreaThe Motley Fool • 04/08/26
CRISPR Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/07/26
Is This Biotech Stock Your Best Shot at Building a Millionaire-Making Position?The Motley Fool • 04/07/26
The Personalized Biotech Flywheel Cathie Wood Built Is Still a Winning Bet Today24/7 Wall Street • 04/03/26
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds ExpectationsSeeking Alpha • 03/31/26
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market TodayZacks Investment Research • 03/25/26
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 03/19/26
From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here24/7 Wall Street • 03/17/26
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These PricesThe Motley Fool • 02/20/26
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall StreetThe Motley Fool • 02/19/26